The role of рАКТ1 expression in diffuse large B-cell lymphoma
https://doi.org/10.20538/1682-0363-2021-3-13-20
Abstract
Aim. To evaluate the prognostic value of pAKT1 expression by tumor cells in patients with diffuse large B-cell lymphoma.
Materials and methods. The study included 90 patients with newly diagnosed diffuse large B-cell lymphoma (DLBCL), who were treated at the clinic of Kirov Research Institute of Hematology and Blood Transfusion from 2014 to 2017 and received standard first-line polychemotherapy according to the R-CHOP regimen. Using immunohistochemical and morphometric methods, the relative number of tumor cells expressing pAKT1 was determined. Using the two-sided Fisher’s exact test, the relationship of different levels of marker expression with clinical and laboratory parameters of patients and long-term treatment results was analyzed. The impact of pAKT1 on the risk of an adverse event was assessed using the Cox regression analysis.
Results. Overexpression of pAKT1 is associated with unfavorable clinical characteristics of patients with DLBCL, excessive expression of the BCL2 and c-Myc oncoproteins, as well as with low rates of overall and progressive survival. Overexpression of pAKT1 is an independent prognostic factor and statistically significantly affects the risk of an adverse outcome in DLBCL.
Conclusion. The degree of pAKT1 expression is an informative criterion that allows to predict the course of diffuse large B-cell lymphoma. It is advisable to use the indicated marker when stratifying patients into risk groups.
Supporting agencies: The study was supported by Kirov Research Institute of Hematology and Blood Transfusion.
About the Authors
E. V. Vaneeva
Kirov Research Institute of Hematology and Blood Transfusion (KRIHBT)
Russian Federation
Russian Federation
72, Krasnoarmeyskaya Str., Kirov, 610027, Russian Federation
V. A. Rosin
Kirov Research Institute of Hematology and Blood Transfusion (KRIHBT)
Russian Federation
Russian Federation
72, Krasnoarmeyskaya Str., Kirov, 610027, Russian Federation
D. A. Diakonov
Kirov Research Institute of Hematology and Blood Transfusion (KRIHBT)
Russian Federation
Russian Federation
72, Krasnoarmeyskaya Str., Kirov, 610027, Russian Federation
A. S. Luchinin
Kirov Research Institute of Hematology and Blood Transfusion (KRIHBT)
Russian Federation
Russian Federation
72, Krasnoarmeyskaya Str., Kirov, 610027, Russian Federation
S. V. Samarina
Kirov Research Institute of Hematology and Blood Transfusion (KRIHBT)
Russian Federation
Russian Federation
72, Krasnoarmeyskaya Str., Kirov, 610027, Russian Federation
N. L. Kochetov
Kirov Research Institute of Hematology and Blood Transfusion (KRIHBT)
Russian Federation
Russian Federation
72, Krasnoarmeyskaya Str., Kirov, 610027, Russian Federation
References
1. Сabattini E., Pileri S.A., Dirnhofer S., Went P., Ascani S., Marafioti T., Tzankov A., Leoncini L., Falini B., Zinzani P.L. Diffuse large B-cell lymphoma: one or more entities? Present controversies and possible tools for its sub classification. Histopathology. 2002; 41 (6): 482–509. DOI: 10.1046/j.1365-2559.2002.01538.x.
2. Sehn L.H., Gascoyne R.D. Diffuse large B-cell lymphoma: optimizing outcome in the context of clinical and biologic heterogeneity. Blood. 2015; 125 (1): 22–32. DOI: 10.1182/blood-2014-05- 577189.
3. Поляцкин И.Л., Артемьева А.С., Криволапов Ю.А. Пересмотренная классификация ВОЗ опухолей гемопоэтической и лимфоидной тканей. 2017 (4-е изд.): опухоли лимфоидной ткани. Архив патологии. 2019; 81 (3): 59–65. DOI: 10.17116/patol 20188006143.
4. Расторгуев С.М., Королева Д.А., Булыгина Е.С., Цыганкова С.В., Гончаров Н.Г., Нарайкин О.С., Габеева Н.Г., Звонков Е.Е., Недолужко А.В. Клиническое и прогностическое значение молекулярных маркеров диффузной В-крупноклеточной лимфомы. Клиническая онкогематология. 2019; 12 (1): 95–100. DOI: 10.21320/2500-2139-2019-12-1-95-100.
5. Самарина С.В., Назарова Е.Л., Минаева Н.В., Зотина Е.Н., Парамонов И.В., Грицаев С.В. Клинико-гематологические показатели прогноза ответа на терапию первой линии у пациентов с диффузной В-крупноклеточной лимфомой. Клиническая онкогематология. 2019; 12 (1): 68–72. DOI: 10.21320/2500-2139-2019-12-1-68-72.
6. Капланов К.Д., Волков Н.П., Клиточенко Т.Ю., Матвеева И.В., Шипаева А.Л., Широкова М.Н., Давыдова Н.В., Гемджян Э.Г., Абрамов Д.С., Коновалов Д.М., Снигур Г.Л., Редбкина Н.А. Результаты анализа регионального регистра пациентов с диффузной В-крупноклеточной лимфомой: факторы риска и проблемы иммунохимиотерапии. Клиническая онкогематология. 2019; 12 (2): 154–164. DOI: 10.21320/2500-2139-2019-12-2-154-164.
7. Ванеева Е.В., Росин В.А., Дьяконов Д.А., Самарина С.В., Рылов А.В. Оценка прогностического значения экспрессии pSTAT3 при диффузной B-крупноклеточной лимфоме на российской выборке пациентов. Сибирский научный медицинский журнал. 2019; 39 (5): 125–133. DOI: 0.15372/SSMJ20190515.
8. Zhang H., Wang X., Dong L., Lv H., Li W., Song Z., Li L., Zhou S., Qiu L., Qian Z., Liu X., Feng L., Meng B., Fu K., Wang X., Pan-Hammarstrom Q., Wang P. Co-expression of PD-L1 and p-AKT is associated with poor prognosis in diffuse large B-cell lymphoma via PD-1/PD-L1 axis activating intracellular AKT/mTOR pathway in tumor cells. Oncotarget. 2016; 7 (22): 33350–33362. DOI: 10.18632/oncotarget.9061.
9. Зейналова П.А., Шолохова Е.Н., Тупицын Н.Н. Прогноз при диффузной В-крупноклеточной лимфоме: некоторые аспекты. Вестник ФГБУ «РОНЦ им. Н.Н. Блохина». 2015; 26 (1): 43–49.
10. Courtney K.D., Corcoran R.B., Engelman J.A. The PI3K pathway as drug target in human cancer. Journal of Clinical Oncology. 2010; 28 (6): 1075–1083. DOI: 10.1200/JCO.2009.25.3641.
11. Kumar А., Rajendran V., Sethumadhavan R., Purohit R. AKT kinase pathway: a leading target in cancer research. Scientific World Journal. 2013; 2013: 756134. DOI: 10.1155/2013/756134.
12. Wang X., Cao X., Sun R., Tang C., Tzankov A., Zhang J., Manyam G.C., Xiao M., Miao Y., Jabbar K., Tan X., Pang Y., Visco C., Xie Y., Dybkaer K., Chiu A., Orazi F., Young K.H. Clinical significance of PTEN deletion, mutation, and loss of pten expression in de novo diffuse large B-cell lymphoma. Neoplasia. 2018; 20 (6): 574–593 DOI: 10.1016/j.neo.2018.03.002.
13. Cтавровская А.А., Генс Г.П. Новое в изучении множественной лекарственной устойчивости клеток рака молочной железы. Успехи молекулярной онкологии. 2015; 2 (1): 39–51. DOI: 10.17650/2313-805X.2015.2.1.039–051.
14. Hans C.P., Weisenburger D.D., Timothy C. et al. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood. 2004; 103 (1): 275–282. DOI: 10.1182/blood-2003-05-1545.
15. Наср М.Р., Перри А.М., Скрабек П. Патология лимфатических узлов для клиницистов; пер. с англ. под ред. Ю.А. Криволапова. М.: Практическая медицина, 2020: 224.
16. Altomare D.A., Testa J.R. Perturbations of the AKT signaling pathway in human cancer. Oncogene. 2005; 24 (50): 7455–7464. DOI: 10.1038/sj.onc.1209085.
17. Wang J., Xu-Monette Z.Y., Jabbar K.J., Shen Q., Manyam G.C., Tzankov A., Visco C., Wang J., Montes-Moreno S., Dybkær K., Tam W., Bhagat G., His E.D., van Krieken J.H., Ponzoni M., Ferreri A.J.M., Wang S., Møller M.B., Piris M.A., Medeiros L.J., Li Y., Pham L.V., Young K.H. AKT hyperactivation and the potential of akt-targeted therapy in diffuse large B-cell lymphoma. American Journal Pathology. 2017; 187 (8): 1700–1716. DOI: 10.1016/j.ajpath.2017.04.009.
18. Hasselblom S., Hansson U., Olsson M., Tore´n L., Bergstrӧm A., Nilsson-Ehle H., Andersson P.-O. High immunohistochemical expression of p-AKT predictsinferior survival in patients with diffuse large B-cell lymphomatreated with immunochemotherapy. British Journal of Haematology. 2010; 149 (4): 560–568. DOI: 10.1111/j.1365-2141.2010.08123.x.
19. Hong J.Y., Hong M.E., Choi M.K., Kim Y.S., Chang W., Maeng C.H., Park S., Lee S.J., Do I.-G., Jo J.-S., Jung S.H., Kim S.J., Ko Y.H., Kim W.S. The impact of activated p-AKT expression on clinical outcomes in diffuse large B-cell lymphoma: A clinicopathological study of 262 cases. Annals of Oncology. 2014; 25 (1): 182–188. DOI: 10.1093/annonc/mdt530.
Review
For citations:
Vaneeva E.V., Rosin V.A., Diakonov D.A., Luchinin A.S., Samarina S.V., Kochetov N.L. The role of рАКТ1 expression in diffuse large B-cell lymphoma. Bulletin of Siberian Medicine. 2021;20(3):13-20. https://doi.org/10.20538/1682-0363-2021-3-13-20
Views:
635
Email this article 